Loading
Innate Pharma Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 19 Jan 2026.
Innate Pharma: what insiders have been doing
This page follows insider dealings at Innate Pharma as filed with AMF, a company from the Healthcare & Pharma sector based in Marseille, France. The group dates from 1999. 6 insiders have disclosed 8 filings since 18 October 2025.
Both sides are active: 4 purchases worth €282k and 1 sale worth €4,710, from 3 insiders and 1 insider respectively. The net balance comes to €277k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €81k, bought by Nicola Beltraminelli and made public on 19 January 2026. Among those who bought: 2 senior executives and 1 finance chief.
Across the 316 companies tracked on its exchange, the median is 6 filings; at 8 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 5 purchases and 21 sales.
In all, 3 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 19 January 2026, 271 days ago. The median gap between a trade and its publication by AMF is 7 days. The regulation allows three business days to notify a trade (MAR article 19).
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Key facts
Headquarters: Marseille, France · Founded: 1999
Source: Wikidata (CC0).
Insider Decl.
51
Thresholds
n/a
Buy Volume
€303,195
5 ops. · all time
Sell Volume
€441,063
21 ops. · all time
Who traded when
BuySaleNicola Beltraminelli2 buys1 sale
Claire DE LINGUA DE SAINT BLANQUAT1 buy
Frederic Lombard1 buy
Since the insiders bought
- -15.4%Entry €1.48 · Close 13 Oct 2026 €1.25
- -16.4%Entry €1.50 · Close 13 Oct 2026 €1.25
- -19.8%Entry €1.56 · Close 13 Oct 2026 €1.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€1.27
Analyst consensus
2 analysts1.00/5
€5.60Target €5.90(+365%)€6.20
Income statement
Revenue€2.8M
EBITDA-€43.6M-1566% margin
Net income-€49.2M-1764.5% margin
Valuation
PER (forward)0.6x
Beta1.19
Balance sheet & cash
Market cap€141.6M
Total debt€22.6M
Free Cash Flow-€34.9M
Profitability & ownership
ROA-46.6%
% insiders17.5%
% institutions10.9%
Last declaration on 14 August 2026
Declarations51 total
1,764,705 shares@ €1.70100.0% of flowActionHors plateforme de négociationISIN FR00103314212026DD1133657
50,000 shares@ €1.61648.7% of flowActionEuronext ParisISIN FR00103314212026DD1086888
Canonical exit: 31 Mar 2026 (T+90)
50,000 shares@ €1.60848.5% of flowActionEuronext ParisISIN FR00103314212026DD1089552
Canonical exit: 31 Mar 2026 (T+90)
50,000 shares@ €1.608100.0% of flowActionEuronext ParisISIN FR00103314212026DD1089243
Canonical exit: 31 Mar 2026 (T+90)
3,000 shares@ €1.572.8% of flowActionEuronext ParisISIN FR00103314212026DD1088617
100,000 shares0Actions gratuiitesHors plateforme de négociationISIN FR00103314212026DD1087352
50,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212026DD1086859
25,000 shares@ €1.608100.0% of flowActionEuronext ParisISIN FR00103314212026DD1086813
Canonical exit: 31 Mar 2026 (T+90)
80,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212025DD1016267
24,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212025DD1016090
28,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212025DD1015979
15,600 shares0ActionHors plateforme de négociationISIN FR00103314212025DD1015881
24,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212025DD1015889
24,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212025DD1015819
20,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212024DD948649
6,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212024DD945593
00Actions gratuitesHors plateforme de négociationISIN FR00103314212022DD874714
00actions gratuitesEuronext ParisISIN FR00103314212022DD873718
00actions gratuitesEuronext ParisISIN FR00103314212022DD873549
00actions gratuitesEuronext ParisISIN FR00103314212022DD873553
25,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212022DD873057
15,000 shares0Actions gratuitesHors plateforme de négociationISIN FR00103314212022DD872730
00Actions gratuitesHors plateforme de négociationISIN FR00103314212022DD854702
00Actions gratuitesHors plateforme de négociationISIN FR00103314212022DD854260
10,000 shares@ €2.39732.2% of flowActionEuronext ParisISIN FR00103314212022DD850530
25 of 51 declarations
About Innate Pharma
Innate Pharma is a French biotechnology company listed on Euronext Paris under the ticker IPH and also traded on Nasdaq as IPHA. Founded in Marseille in 1999, the company has built its strategy around immuno-oncology, with a focus on developing innovative cancer therapies that harness the immune system. Its business model is centered on discovery, clinical development, and the monetization of proprietary and partnered assets, with a long-term objective of creating value through a differentiated pipeline rather than through commercialized products.
Innate Pharma is best described as a clinical-stage biopharmaceutical company with a pipeline structured around several core programs. Its most advanced internal asset is lacutamab, an antibody targeting KIR3DL2, being developed in cutaneous T-cell lymphomas and certain hematologic malignancies. The company is also advancing IPH4502, a nectin-4 antibody-drug conjugate, together with next-generation ADC and multispecific antibody programs. Among its notable partnered assets are monalizumab, co-developed with AstraZeneca, and IPH5201, another AstraZeneca-partnered oncology program. This blend of internal innovation and major pharmaceutical partnerships is central to Innate Pharma’s industrial and financial positioning.
Read moreShow less
The company has established its scientific reputation through expertise in innate immune biology, especially natural killer cells, and through its ability to identify novel oncology targets. Its R&D approach emphasizes first-in-class or best-in-class mechanisms and biomarker-driven development in order to improve patient selection and clinical probability of success. Over time, Innate Pharma has also expanded its credibility through collaborations with major pharma groups, particularly AstraZeneca. In 2025, Sanofi subscribed to a capital increase of nearly €15 million, underlining continued external interest in the company’s platform and pipeline.
Geographically, Innate Pharma remains anchored in Marseille while operating internationally through its clinical trial network, business partnerships, and U.S. market presence. The company has recently reiterated a clear prioritization strategy, concentrating resources on its highest-value clinical assets. As of December 31, 2025, cash and cash equivalents stood at €44.8 million, with management indicating a cash runway through the end of Q3 2026. Innate Pharma therefore remains a flagship French biotech name: scientifically ambitious, clinically exposed, and highly leveraged to trial readouts, partnering opportunities, and the successful translation of its pipeline into long-term shareholder value.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
